← ANALYST RATINGS · TIPRANKS
Vericel (VCEL): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $60.25, the highest $72.00, the lowest $52.00. The average is +50.1% from the last price of $40.13.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Richard Newitter★★★★★★★★★★#1772 · hits 48% · avg +6.6% | Truist Financial | $58.00 → $52.00−10.3% | Buy | +29.6% | Reiterated | 14.10.26on TipRanks 08:35 | +1.0%next day +1.6% | ↗ |
| Unknown Analyst | Leerink Partners | $59.00 | Buy | +47.0% | Reiterated | 18.09.26on TipRanks Sep 21 21:00 | −0.2%next day −2.7% · 5 days −2.0% | ↗ |
| Josh Jennings★★★★★★★★★★#3537 · hits 46% · avg +3.0% | TD Cowen | $58.00 | Buy | +44.5% | Reiterated | 04.09.26on TipRanks 07:30 | −0.3%next day −2.2% · 5 days −0.3% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $48.00 → $44.00−8.3% | Hold | +9.6% | Downgrade | 30.08.26on TipRanks Aug 29 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $49.00 → $44.00−10.2% | Hold | +9.6% | Downgrade | 30.08.26on TipRanks Aug 29 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $48.00 → $43.00−10.4% | Hold | +7.2% | Downgrade | 30.08.26on TipRanks Aug 29 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $45.00 → $42.00−6.7% | Hold | +4.7% | Reiterated | 30.08.26on TipRanks Aug 29 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $48.00 → $44.00−8.3% | Hold | +9.6% | Downgrade | 30.08.26on TipRanks Aug 29 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $49.00 → $44.00−10.2% | Hold | +9.6% | Downgrade | 30.08.26on TipRanks Aug 29 23:05 | — | |
| Swayampakula Ramakanth★★★★★★★★★★#445 · hits 47% · avg +21.2% | H.C. Wainwright | $70.00 → $72.00+2.9% | Buy | +79.4% | Reiterated | 31.07.26on TipRanks Jul 28 06:15 | +2.8%next day +1.3% · 5 days −4.9% | ↗ |
| Caitlin Roberts★★★★★★★★★★#1832 · hits 65% · avg +14.7% | Canaccord Genuity | $58.00 | Buy | +44.5% | Reiterated | 24.06.26on TipRanks Jun 25 07:18 | +3.3%next day +2.8% · 5 days +6.6% | ↗ |
| Ryan Zimmerman★★★★★★★★★★#3375 · hits 46% · avg +3.3% | BTIG | — | Hold | — | Reiterated | 05.04.26on TipRanks Apr 6 06:45 | −0.6%next day −2.2% · 5 days −3.1% | ↗ |
| Unknown Analyst | Ladenburg Thalmann & Co. | $62.00 | Buy | +54.5% | Reiterated | 27.02.26on TipRanks 11:20 | −4.8%next day −1.0% · 5 days −3.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Vericel
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $63.00 at a price of $40.14 (+57.0%); now: $60.25 at $40.13 (+50.1%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 4 | 1 | 1 | 0 |
| Buy | 2 | 4 | 6 | 6 | 6 | 4 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.06 (from $0.02 to $0.10). Last quarter: $0.04.
Sales
Next quarter’s sales estimate — $78M (from $77M to $78M). Last quarter: $77M.
Best top-analyst consensus in the sector · Healthcare
About Vericel
- CEO: Dominick C. Colangelo
- Employees: 398
- 25 Blue Sky Drive, Burlington, MA, 01803, US
- vcel.com
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Data from the stock’s TipRanks forecast page, read 158 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗